ACRX Acelrx Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACRX

Price (delayed)

$1.11

Market cap

$12.13M

P/E Ratio

0.18

Dividend/share

N/A

EPS

$6.16

Enterprise value

$2.14M

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers ...

Highlights
Acelrx Pharmaceuticals's debt has plunged by 80% YoY and by 38% from the previous quarter
The price to earnings (P/E) is 64% lower than the last 4 quarters average of 0.5
ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter
The gross margin has dropped by 105% year-on-year but it has grown by 22% since the previous quarter
ACRX's revenue is down by 42% YoY and by 25% QoQ
The quick ratio has declined by 39% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.acelrx.com
Peers: DRRX CARA

Key stats

What are the main financial stats of ACRX
Market
Shares outstanding
10.92M
Market cap
$12.13M
Enterprise value
$2.14M
Valuations
Price to earnings (P/E)
0.18
Price to book (P/B)
0.85
Price to sales (P/S)
9.1
EV/EBIT
0.04
EV/EBITDA
0.04
EV/Sales
1.61
Earnings
Revenue
$1.33M
EBIT
$49.12M
EBITDA
$50.61M
Free cash flow
-$25.02M
Per share
EPS
$6.16
Free cash flow per share
-$2.3
Book value per share
$1.3
Revenue per share
$0.12
TBVPS
$2.41
Balance sheet
Total assets
$26.29M
Total liabilities
$12.05M
Debt
$3.37M
Equity
$14.24M
Working capital
$7.89M
Liquidity
Debt to equity
0.24
Current ratio
1.83
Quick ratio
1.41
Net debt/EBITDA
-0.2
Margins
EBITDA margin
3,808.1%
Gross margin
-36%
Net margin
3,632.6%
Operating margin
-2,480.5%
Efficiency
Return on assets
96.5%
Return on equity
178.3%
Return on invested capital
229%
Return on capital employed
291.9%
Return on sales
3,696.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACRX stock price

How has the Acelrx Pharmaceuticals stock price performed over time
Intraday
16.84%
1 week
40.31%
1 month
64.15%
1 year
-74.89%
YTD
-50.88%
QTD
68.69%

Financial performance

How have Acelrx Pharmaceuticals's revenue and profit performed over time
Revenue
$1.33M
Gross profit
-$478,000
Operating income
-$32.97M
Net income
$48.28M
Gross margin
-36%
Net margin
3,632.6%
The gross margin has dropped by 105% year-on-year but it has grown by 22% since the previous quarter
ACRX's operating margin has shrunk by 80% YoY and by 20% QoQ
ACRX's revenue is down by 42% YoY and by 25% QoQ
ACRX's gross profit is up by 42% QoQ but it is down by 18% YoY

Growth

What is Acelrx Pharmaceuticals's growth rate over time

Valuation

What is Acelrx Pharmaceuticals stock price valuation
P/E
0.18
P/B
0.85
P/S
9.1
EV/EBIT
0.04
EV/EBITDA
0.04
EV/Sales
1.61
The price to earnings (P/E) is 64% lower than the last 4 quarters average of 0.5
ACRX's EPS is up by 8% since the previous quarter
ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter
The P/B is 6% less than the last 4 quarters average of 0.9
ACRX's price to sales (P/S) is 80% lower than its 5-year quarterly average of 45.6 and 37% lower than its last 4 quarters average of 14.5
ACRX's revenue is down by 42% YoY and by 25% QoQ

Efficiency

How efficient is Acelrx Pharmaceuticals business performance
The company's return on equity has shrunk by 54% QoQ
The company's return on invested capital has surged by 51% QoQ
ACRX's return on sales is up by 34% since the previous quarter
ACRX's ROA is up by 28% since the previous quarter

Dividends

What is ACRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRX.

Financial health

How did Acelrx Pharmaceuticals financials performed over time
Acelrx Pharmaceuticals's total assets is 118% higher than its total liabilities
ACRX's total liabilities has shrunk by 89% YoY and by 53% QoQ
Acelrx Pharmaceuticals's total assets has shrunk by 63% YoY and by 45% QoQ
Acelrx Pharmaceuticals's debt is 76% less than its equity
The debt to equity has soared by 156% YoY but it has contracted by 4% from the previous quarter
ACRX's equity has soared by 137% YoY but it is down by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.